Literature DB >> 2572685

c-erbB-2 oncogene product staining in gastric adenocarcinoma. An immunohistochemical study.

V G Falck1, W J Gullick.   

Abstract

The c-erbB-2 oncogene has been shown to be amplified in a variety of human adenocarcinomas. Antibodies to the protein product, p185, have been used for immunostaining of paraffin-embedded material, and have demonstrated that high levels of c-erbB-2 protein expression correlate with gene amplification under certain conditions. In studies by others, amplification has been demonstrated in 40 per cent of tubular type adenocarcinomas of the stomach, and an immunohistochemical study on frozen tissue has demonstrated staining in 3 out of 10 cases. Our study, using paraffin-embedded material, demonstrates staining in 19 per cent of 126 cases using a polyclonal antibody. Of the positive cases, 75 per cent were tubular or papillary type (P less than 0.025), and prominent staining was restricted to this group. Three cases showed well-defined positive areas in keeping with clonal expression of p185. No specific staining of normal or dysplastic epithelium adjacent to the carcinomas was found.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2572685     DOI: 10.1002/path.1711590204

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  25 in total

1.  c-erbB-2 oncogene product expression and prognosis in gastric carcinoma.

Authors:  D A Hilton; K P West
Journal:  J Clin Pathol       Date:  1992-05       Impact factor: 3.411

2.  Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus.

Authors:  J Jankowski; G Coghill; D Hopwood; K G Wormsley
Journal:  Gut       Date:  1992-08       Impact factor: 23.059

3.  Amplification and overexpression of the c-erbB-2 protooncogene in human gastric cancer.

Authors:  K Sasaki; Y Tomita; M Azuma; S Shida; B Simizu
Journal:  Gastroenterol Jpn       Date:  1992-04

4.  Prognostic significance of immunohistochemical expression of EGFR and C-erbB-2 oncoprotein in curatively resected gastric cancer.

Authors:  Hong Suk Song; Young Rok Do; In Ho Kim; Soo Sang Sohn; Kun Young Kwon
Journal:  Cancer Res Treat       Date:  2004-08-31       Impact factor: 4.679

5.  Expression of c-erbB-2 oncoprotein in gastric carcinoma: correlation with histopathologic characteristics and analysis of Ki-67.

Authors:  A Dursun; A Poyraz; B Celik; G Akyol
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

Review 6.  Molecular biology and gastric carcinoma.

Authors:  P A Wright; G T Williams
Journal:  Gut       Date:  1993-02       Impact factor: 23.059

7.  NEU overexpression in the furan rat model of cholangiocarcinogenesis compared with biliary ductal cell hyperplasia.

Authors:  A E Sirica; S Radaeva; N Caran
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

8.  Expression of Her2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma.

Authors:  J Jaehne; C Urmacher; H T Thaler; H Friedlander-Klar; C Cordon-Cardo; H J Meyer
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

9.  Expression of the c-erbB-2 proto-oncogene product and nuclear DNA content in benign and malignant human breast parenchyma.

Authors:  H Schimmelpenning; E T Eriksson; U G Falkmer; E Azavedo; G Svane; G U Auer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

10.  Adrenocorticotropin-Producing Pituitary Carcinoma with Expression of c-erbB-2 and High PCNA Index: A Comparative Study with Pituitary Adenomas and Normal Pituitary Tissues.

Authors:  Vania Nose-Alberti; Maria Isabel S. Mesquita; Luciana C. Martin; Marcia J. Kayath
Journal:  Endocr Pathol       Date:  1998       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.